XML 46 R33.htm IDEA: XBRL DOCUMENT v3.26.3
Revenues (Tables)
 9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Product Revenue The table below presents the Company’s gross and net product revenue ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Product revenue - gross115,784 127,103 331,713 355,965 
Less: Rebates and sales returns(8,136)(11,742)(22,758)(25,870)
Product revenue - net107,648 115,361 308,955 330,095 
Schedule of Disaggregation of Net Revenue
The following table presents the Company’s net revenue by commercial program ($ in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
ZEJULA32,284 42,432 94,330 133,002 
VYVGART / VYVGART Hytrulo24,071 27,727 65,488 72,329 
NUZYRA21,089 15,430 54,448 44,840 
OPTUNE7,821 12,657 32,093 36,375 
QINLOCK8,829 8,901 27,404 25,946 
XACDURO8,421 6,445 24,950 12,184 
AUGTYRO2,822 1,677 6,827 4,702 
KarXT2,015 — 2,567 — 
Other (i)296 92 848 717 
Product revenue - net107,648 115,361 308,955 330,095 
(i)Other includes product candidates sold in patient programs prior to commercialization.